3 results
Approved WMOPending
Primary objectives of INTACT III are:1) to prospectively compare the efficacy of Sacral Nerve Stimulation (SNS) with BOTOX® 100 U related to the Patient Perception of Bladder Condition (PPBC) questionnaire (Coyne 2006) and the reduction of urinary…
Approved WMOCompleted
Compare Progression Free Survival (PFS) for brivanib versus placebo in subjects with advanced solid tumors with FGF-2 over-expression and who have obtained stable disease after 12 weeks of treatment with brivanib separately for each tumor.
Approved WMOCompleted
To estimate the efficacy of erlotinib administered as a single agent to chemo-naïve NSCLC patients as determined by the non progression rate (NPR) at 8 weeks.